ARQT
BEARISH
$22.75
Live
Arcutis Biotherapeutics, Inc. · NASDAQ
Target $34.75
(+52.7%)
$11.86
52W Range
$31.77
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$2.82B
P/E
N/A
ROE
-9.3%
Profit margin
-4.3%
Debt/Equity
0.6
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.
Key Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Forward P/E of 17.79 is relatively attractive compared to sector average of 164.64
Analyst consensus is strong_buy, indicating potential upside expectation
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
No free cash flow or operating cash flow data available, indicating potential liquidity risk
Price/Sales of 7.50 and Price/Book of 14.81 suggest significant overvaluation relative to fundamentals
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
20
70
40
15
0
AI Verdict
weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative profitability and return metrics, High valuation multiples without earnings support, Significant insider selling, Lack of cash flow and intrinsic value
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 17.79 is below sector average
- High gross margin suggests pricing strength
Watchpoints
- No Graham Number or intrinsic value available
- Price/Sales of 7.50 is high for a loss-making company
- Price/Book of 14.81 indicates extreme premium valuation
Future
70/100
Ref Growth rates
Positives
- 81.5% YoY revenue growth is exceptional
- Strong analyst target price of $34.75 implies growth optimism
Watchpoints
- No earnings growth data available
- Negative profit margin persists despite growth
- No free cash flow data to support sustainability
Past
40/100
Ref Historical trends
Positives
- 1Y return of +53.6% and 3Y return of +98.3% show strong historical performance
Watchpoints
- 5Y return of -30.1% indicates long-term underperformance
- Recent 1M and 1W declines of -14.4% and -5.2% show weakening momentum
- Piotroski F-Score of 1 suggests deteriorating fundamentals over time
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 3.17 and quick ratio of 2.83 indicate strong liquidity
- Debt/Equity of 0.60 is moderate
Watchpoints
- Piotroski F-Score of 1/9 is extremely low, indicating financial distress
- Negative ROE and ROA suggest poor capital utilization
- No Altman Z-Score available, but low F-Score implies distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$22.75
Analyst Target
$34.75
Upside/Downside
+52.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ARQT and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
Primary
|
-30.1% | +98.3% | +53.6% | +31.6% | -14.4% | -5.2% |
|
HAE
Haemonetics Corporation
Peer
|
-11.4% | -27.8% | -3.5% | +18.1% | +11.9% | -1.1% |
|
TARS
Tarsus Pharmaceuticals, Inc.
Peer
|
+124.0% | +341.3% | +36.0% | -7.3% | +2.3% | -9.2% |
|
CON
Concentra Group Holdings Parent, Inc.
Peer
|
+3.3% | +3.3% | +8.6% | +9.8% | +3.7% | -0.2% |
|
TXG
10x Genomics, Inc.
Peer
|
-88.0% | -57.2% | +199.1% | +76.3% | +20.0% | -7.4% |
ARQ
Arcutis Biotherapeutics, Inc.
Primary
5Y
-30.1%
3Y
+98.3%
1Y
+53.6%
6M
+31.6%
1M
-14.4%
1W
-5.2%
HAE
Haemonetics Corporation
Peer
5Y
-11.4%
3Y
-27.8%
1Y
-3.5%
6M
+18.1%
1M
+11.9%
1W
-1.1%
TAR
Tarsus Pharmaceuticals, Inc.
Peer
5Y
+124.0%
3Y
+341.3%
1Y
+36.0%
6M
-7.3%
1M
+2.3%
1W
-9.2%
CON
Concentra Group Holdings Parent, Inc.
Peer
5Y
+3.3%
3Y
+3.3%
1Y
+8.6%
6M
+9.8%
1M
+3.7%
1W
-0.2%
TXG
10x Genomics, Inc.
Peer
5Y
-88.0%
3Y
-57.2%
1Y
+199.1%
6M
+76.3%
1M
+20.0%
1W
-7.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
17.79
PEG Ratio
N/A
P/B Ratio
14.81
P/S Ratio
7.5
EV/Revenue
7.22
EV/EBITDA
-359.13
Market Cap
$2.82B
Profitability
Profit margins and return metrics
Profit Margin
-4.29%
Operating Margin
14.2%
Gross Margin
90.24%
ROE
-9.3%
ROA
-1.96%
Growth
Revenue and earnings growth rates
Revenue Growth
+81.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.6
Moderate
Current Ratio
3.17
Strong
Quick Ratio
2.83
Excellent
Cash/Share
$1.78
Healthcare Sector Comparison
Comparing ARQT against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-9.3%
This Stock
vs
-88.14%
Sector Avg
-89.4%
(Below Avg)
Profit Margin
-4.29%
This Stock
vs
-16.28%
Sector Avg
-73.6%
(Weaker)
Debt to Equity
0.6
This Stock
vs
2.66
Sector Avg
-77.4%
(Less Debt)
Revenue Growth
81.5%
This Stock
vs
124.04%
Sector Avg
-34.3%
(Slower)
Current Ratio
3.17
This Stock
vs
4.47
Sector Avg
-29.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BEARISH | $2.82B | - | -9.3% | -4.3% | $22.75 | |
|
HAE
Haemonetics Corporation
|
BULLISH | $2.81B | 16.66 | 19.3% | 13.3% | $60.48 | Compare |
|
TARS
Tarsus Pharmaceuticals, Inc.
|
NEUTRAL | $2.81B | - | -23.4% | -14.7% | $65.97 | Compare |
|
CON
Concentra Group Holdings...
|
NEUTRAL | $2.93B | 17.55 | 48.1% | 7.7% | $22.82 | Compare |
|
TXG
10x Genomics, Inc.
|
NEUTRAL | $2.93B | - | -5.8% | -6.8% | $22.97 | Compare |
ARQT
Arcutis...
BEARISH
Mkt Cap
$2.8B
P/E
-
ROE
-9.3%
Price
$22.75
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | LEONARD KEITH R JR | Director | Option Exercise | 39,272 | $325,231 |
| 2026-03-02 | LEONARD KEITH R JR | Director | Sale | 39,272 | $997,195 |
| 2026-03-02 | BURNETT PATRICK | Officer | Sale | 6,287 | $158,320 |
| 2026-03-02 | MATSUDA MASARU | Officer | Sale | 12,058 | $313,877 |
| 2026-03-02 | WATANABE TODD FRANKLIN | Chief Executive Officer | Sale | 37,349 | $940,528 |
| 2026-03-02 | WELGUS HOWARD G | Director | Sale | 10,000 | $256,518 |
| 2026-03-02 | EDWARDS LARRY TODD | Officer | Sale | 3,687 | $92,846 |
| 2026-03-02 | VAIRAVAN LATHA | Chief Financial Officer | Sale | 2,853 | $71,844 |
| 2026-02-27 | BURNETT PATRICK | Officer | Stock Award | 46,750 | - |
| 2026-02-27 | MATSUDA MASARU | Officer | Stock Award | 37,000 | - |
| 2026-02-27 | WATANABE TODD FRANKLIN | Chief Executive Officer | Stock Award | 102,000 | - |
| 2026-02-27 | EDWARDS LARRY TODD | Officer | Stock Award | 30,000 | - |
| 2026-02-27 | VAIRAVAN LATHA | Chief Financial Officer | Stock Award | 27,000 | - |
| 2026-02-04 | BURNETT PATRICK | Officer | Sale | 13,469 | $346,455 |
| 2026-02-02 | MATSUDA MASARU | General Counsel | Sale | 40,638 | $1,027,293 |
LEONARD KEITH R JR
Director
2026-03-02
39,272 shares
·
$325,231
LEONARD KEITH R JR
Director
2026-03-02
39,272 shares
·
$997,195
BURNETT PATRICK
Officer
2026-03-02
6,287 shares
·
$158,320
MATSUDA MASARU
Officer
2026-03-02
12,058 shares
·
$313,877
WATANABE TODD FRANKLIN
Chief Executive Officer
2026-03-02
37,349 shares
·
$940,528
WELGUS HOWARD G
Director
2026-03-02
10,000 shares
·
$256,518
EDWARDS LARRY TODD
Officer
2026-03-02
3,687 shares
·
$92,846
VAIRAVAN LATHA
Chief Financial Officer
2026-03-02
2,853 shares
·
$71,844
BURNETT PATRICK
Officer
2026-02-27
46,750 shares
MATSUDA MASARU
Officer
2026-02-27
37,000 shares
WATANABE TODD FRANKLIN
Chief Executive Officer
2026-02-27
102,000 shares
EDWARDS LARRY TODD
Officer
2026-02-27
30,000 shares
VAIRAVAN LATHA
Chief Financial Officer
2026-02-27
27,000 shares
BURNETT PATRICK
Officer
2026-02-04
13,469 shares
·
$346,455
MATSUDA MASARU
General Counsel
2026-02-02
40,638 shares
·
$1,027,293
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
8 analysts
Mizuho
2026-03-02
Outperform
Outperform
Guggenheim
2026-02-27
Buy
Buy
TD Cowen
2026-02-26
Buy
Buy
HC Wainwright & Co.
2026-02-26
Buy
Buy
Needham
2026-02-26
Buy
Buy
Needham
2026-01-26
Buy
Buy
Mizuho
2025-11-28
Outperform
Outperform
Goldman Sachs
2025-10-30
Neutral
Neutral
Needham
2025-10-28
Buy
Buy
Past News Coverage
Recent headlines mentioning ARQT from our newsroom.
Newest → oldest
No matching news yet.